Dr. O'Connor on Ongoing Breast Cancer Research

Kathleen L. O'Connor, MD
Published: Tuesday, Aug 30, 2016


Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

A deeper understanding of the heterogeneity of breast cancer has evolved the treatment landscape, O'Connor explains. Some subtypes, such as luminal A cancers, are treated with hormonal therapy, while triple-negative subtypes do not yet have effective therapies. Trastuzumab (Herceptin) has demonstrated efficacy for patients in a number of breast cancer subtypes, she adds.

UK Markey is involved in research dedicated to understanding triple-negative breast cancer (TNBC). A current focus by the NCI-designated cancer center is a pilot study aimed at understanding the genetics of TNBC and how these tumors respond to therapy.

Kathleen L. O'Connor, MD, professor, associate director of Cancer Education, Department of Molecular and Cellular Biochemistry, University of Kentucky Markey Cancer Center, discusses the ongoing research in the field of breast cancer.

A deeper understanding of the heterogeneity of breast cancer has evolved the treatment landscape, O'Connor explains. Some subtypes, such as luminal A cancers, are treated with hormonal therapy, while triple-negative subtypes do not yet have effective therapies. Trastuzumab (Herceptin) has demonstrated efficacy for patients in a number of breast cancer subtypes, she adds.

UK Markey is involved in research dedicated to understanding triple-negative breast cancer (TNBC). A current focus by the NCI-designated cancer center is a pilot study aimed at understanding the genetics of TNBC and how these tumors respond to therapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x